Screener
Vanda Pharmaceuticals VNDA Q3 2026 earnings
Reported October 28, 2026 · After market close
Revenue$69.8MBeat by $612.6K
EPS-$0.37Beat by $0.31
Revenue estimate$69.2M
EPS estimate-$0.68
“Looking ahead, with the commercial launch of BYSANTI expected in the fourth quarter, the Quimilza BLA under FDA review with a December PDUFA date, and positive Phase III results supporting potential expansions for NEREUS in GLP-1-induced vomiting and HETLIOZ in Delayed Sleep-Wake Phase Disorder, we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value.”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
FAQ
- When did Vanda Pharmaceuticals report Q3 2026 earnings?
- Vanda Pharmaceuticals (VNDA) reported Q3 2026 earnings on October 28, 2026 after market close.
- What were Vanda Pharmaceuticals's Q3 2026 revenue and EPS?
- Vanda Pharmaceuticals reported revenue of $69.8M and eps of $-0.37 for Q3 2026.
- Did Vanda Pharmaceuticals beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $69.2M by $612.6K. EPS beat the consensus estimate of $-0.68 by $0.31.
- How did Vanda Pharmaceuticals's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 24.1% from $56.3M a year earlier and eps grew 2.6% from $-0.38.
- Where can I find Vanda Pharmaceuticals's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-067886) and the 10-Q periodic report (0001347178-26-000002) directly on SEC EDGAR. The filing index links above go to sec.gov.
